Precision BioSciences, Inc. (DTIL) Discusses Phase 1 ELIMINATE-B Data for PBGENE-HBV in Chronic Hepatitis B Transcript

🇺🇸 Seeking Alpha (US) —
Precision BioSciences, Inc. (DTIL) Discusses Phase 1 ELIMINATE-B Data for PBGENE-HBV in Chronic Hepatitis B Transcript

AI Summary

Precision BioSciences discussed Phase 1 ELIMINATE-B data for PBGENE-HBV, an investigational program targeting chronic hepatitis B. The supplied information does not specify the study's results or safety findings.

Markets Health Precision BioSciences PBGENE-HBV hepatitis B Phase 1 clinical trial

Read original source →